PHARMACEUTICAL giant Amgen is to create 100 jobs as part of a €150m investment at its Dun Laoghaire base.
A further 350 construction jobs will also be created during the building period.
The move comes nearly a year after Amgen bought the former Pfizer plan with the retention of the 280 positions at the site.
"As we expand internationally, Dun Laoghaire will enhance our global production capability, ensuring continuity of supply of Amgen medicines for seriously ill patients worldwide,'' said Martin VanTrieste, senior vice president of Quality at Amgen.
According to IDA Ireland's chief executive Barry O'Leary, Ireland is the largest development and manufacturing location in the world for biopharmaceuticals, outside the US.
''Amgen's decision to locate this strategically important investment here is a clear endorsement of Ireland's recognised strengths in this field. By providing the right environment and a commitment to support R&D investment, Ireland has positioned itself as a leading location for biotech investments,'' he said.
''The strategic and collaborative nature of this investment coupled with the strong reputation of the facility and staff, make this a truly excellent win for both Ireland and Amgen," he added.
Taoiseach Enda Kenny said that this was a really positive development for Ireland and the region.
''It is a great example of industry working with the local community and it sends a signal of confidence in Dublin and Ireland as the location of choice for biotechnology and pharmaceutical investment outside the US,'' he added.